MPM and Longwood-backed Werewolf Therapeutics grabs $56 million to take tumors by night
Backed with the team from his last company, one of the key developers behind Keytruda has a new warchest in the race to bring immunotherapy into the tumor micro-environment.
Dan Hicklin, who oversaw Merck’s I/O portfolio and helped develop several other cancer drugs, is the founder and president of Werewolf Therapeutics, a company that aims to “shapeshift” its way into tumors and tear them apart from within. With the exception of the COO, its leadership is entirely seeded from Potenza Therapeutics, the antibody company Hicklin sold to Astellas for $165 million upfront last December. They’ll even use the same lab space.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters